State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia

Journal of Cellular Physiology

Volumn 233, Issue 2, 2018, Pages 888-900

  Mirzaei, Hamed ^a   Fathullahzadeh, Sima ^b   Khanmohammadi, Razieh ^c   Darijani, Mansoreh ^d   Momeni, Fatemeh ^e   Masoudifar, Aria ^f   Goodarzi, Mohammad ^g   Mardanshah, Omid ^h   Stenvang, Jan ⁱ   Jaafari, Mahmoud Reza ^j   Mirzaei, Hamid Reza ^k  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^g UNIVERSITY OF LEUVEN   (Belgium)

^h ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^k TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

biomarker; chronic lymphocytic leukemia; diagnosis; MicroRNA; therapy

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; MICRORNA; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; EXOSOME; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM MALIGNANCY; HUMAN; NONHUMAN; REVIEW; TREATMENT RESPONSE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 85014805815     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25799     Document Type: Review

References (134)

1. Ahmed, F., Muzaffar, R., Fernandes, H., Tu, Y., Albalooshi, B., & Osman, M. M. (2016). Skeletal metastasis as detected by 18F-FDG PET with negative CT of the PET/CT: Frequency and impact on cancer staging and/or management. Frontiers in Oncology, 10(6), 208.
2. Al-Harbi, S., Choudhary, G. S., Ebron, J. S., Hill, B. T., Vivekanathan, N., Ting, A. H., … Almasan, A. (2015). MiR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. Molecular Cancer, 14(1), 1.
3. Alvi, A. J., Austen, B., Weston, V. J., Fegan, C., MacCallum, D., Gianella-Borradori, A., … Stankovic, T. (2005). A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood, 105(11), 4484–4491.
4. Ardekani, A. M., & Naeini, M. M. (2011). The role of microRNAs in human diseases. Avicenna Journal of Medical Biotechnology, 2(4), 161–180.
5. Balatti, V., Acunzo, M., Pekarky, Y., & Croce, C. M. (2016). Novel mechanisms of regulation of miRNAs in CLL. Trends in Cancer, 2(3), 134–143.
6. Balatti, V., Pekarky, Y., & Croce, C. M. (2015). Role of microRNA in chronic lymphocytic leukemia onset and progression. Journal of Hematology & Oncology, 8(1), 1.
7. Balatti, V., Rizzotto, L., Miller, C., Palamarchuk, A., Fadda, P., Pandolfo, R., … Lozanski, A. (2015). TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 112(7), 2169–2174.
8. Bartel, T. B., Haessler, J., Brown, T. L., Shaughnessy, J. D., van Rhee, F., Anaissie, E., … Epstein, J. (2009). F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 114(10), 2068–2076.
9. Berg, V., Rusch, M., Vartak, N., Jüngst, C., Schauss, A., Waldmann, H., … Hallek, M. (2015). MiRs-138 and-424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL. Blood, 125(19), 2948–2957.
10. Binet, J., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., … Gremy, F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48(1), 198–206.
11. Bomben, R., Gobessi, S., Dal Bo, M., Volinia, S., Marconi, D., Tissino, E., … Gaidano, G. (2012). The miR-17∼ 92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia, 26(7), 1584–1593.
12. Burger, J. A., & Chiorazzi, N. (2013). B cell receptor signaling in chronic lymphocytic leukemia. Trends in Immunology, 34(12), 592–601.
13. Calame, K. (2007). MicroRNA-155 function in B cells. Immunity, 27(6), 825–827.
14. Calin, G. A., Cimmino, A., Fabbri, M., Ferracin, M., Wojcik, S. E., Shimizu, M., … Aqeilan, R. I. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences, 105(13), 5166–5171.
15. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., … Rai, K. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 99(24), 15524–15529.
16. Calin, G. A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., … Dono, M. (2004). MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America, 101(32), 11755–11760.
17. Chavez, J. C., Kharfan-Dabaja, M. A., Kim, J., Yue, B., Dalia, S., Pinilla-Ibarz, J., … Locke, F. L. (2014). Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leukemia Research, 38(10), 1165–1172.
18. Chen, X.-M. (2009). MicroRNA signatures in liver diseases. World Journal of Gastroenterology, 15(14), 1665–1672.
19. Chen, C.-Z., & Lodish, H. F. (2005). MicroRNAs as Regulators of Mammalian Hematopoiesis. Seminars in immunology, Elsevier, 17(2), 155–165.
20. Chen, C., & Puvvada, S. (2016). Prognostic factors for chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 11(1), 37–42.
21. Chen, L., Widhopf, G., Huynh, L., Rassenti, L., Rai, K. R., Weiss, A., & Kipps, T. J. (2002). Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood, 100(13), 4609–4614.
22. Chen, C.-Z., Li, L., Lodish, H. F., & Bartel, D. P. (2004). MicroRNAs modulate hematopoietic lineage differentiation. Science, 303(5654), 83–86.
23. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., OȇBrien, S., & Rai, K. R. (1996). National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood, 87(12), 4990–4997.
24. Chiorazzi, N., Rai, K. R., & Ferrarini, M. (2005). Chronic lymphocytic leukemia. New England Journal of Medicine, 352(8), 804–815.
25. Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., … Dono, M. (2005). MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 102(39), 13944–13949.
26. Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., & Croce, C. M. (2006). Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eµ-miR155 transgenic mice. Proceedings of the National Academy of Sciences, 103(18), 7024–7029.
27. Craxton, A., Jiang, A., Kurosaki, T., & Clark, E. A. (1999). Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. Journal of Biological Chemistry, 274(43), 30644–30650.
28. Cui, B., Chen, L., Zhang, S., Mraz, M., Fecteau, J.-F., Yu, J., … Rassenti, L. Z. (2014). MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood, 124(4), 546–554.
29. Dimopoulos, M., Terpos, E., Comenzo, R., Tosi, P., Beksac, M., Sezer, O., … Rajkumar, S. V. (2009). International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia, 23(9), 1545–1556.
30. Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krِöber, A., Bullinger, L., … Lichter, P. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343(26), 1910–1916.
31. Dong, L., Bi, K., Huang, N., & Chen, C. (2016). Biological analysis of chronic lymphocytic leukemia: Integration of mRNA and microRNA expression profiles. Genetics and Molecular Research: GMR, 15(1). http://doi.org/10.4238/gmr.15017170
32. Drexler, H. G., Janssen, J., Brenner, M. K., Hoffbrand, A. V., & Bartram, C. R. (1989). Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore. Blood, 73(6), 1656–1663.
33. Durak, B., Akay, O. M., Aslan, V., Ozdemir, M., Sahin, F., Artan, S., & Gülbas, Z. (2009). Prognostic impact of chromosome alterations detected by FISH in Turkish patients with B-cell chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 188(2), 65–69.
34. Eichhorst, B. F., Fischer, K., Fink, A.-M., Elter, T., Wendtner, C. M., Goede, V., … Ritgen, M. (2011). Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: Results of a meta-analysis. Blood, 117(6), 1817–1821.
35. Fabbri, G., & Dalla-Favera, R. (2016). The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer, 16(3), 145–162.
36. Fais, F., Ghiotto, F., Hashimoto, S., Sellars, B., Valetto, A., Allen, S. L., … Rassenti, L. Z. (1998). Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. Journal of Clinical Investigation, 102(8), 1515.
37. Farahani, M., Rubbi, C., Liu, L., Slupsky, J. R., & Kalakonda, N. (2015). CLL exosomes modulate the transcriptome and behaviour of recipient stromal cells and are selectively enriched in miR-202-3p. PLoS ONE, 10(10), 0141429.
38. Fathullahzadeh, S., Mirzaei, H., Honardoost, M., Sahebkar, A., & Salehi, M. (2016). Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Therapy, 23(10), 327–332.
39. Fernando, T. R., Rodriguez-Malave, N. I., & Rao, D. S. (2012). MicroRNAs in B cell development and malignancy. Journal of Hematology & Oncology, 5(1), 1.
40. Ferrarini, M., Cutrona, G., Neri, A., & Morabito, F. (2012). Prognostic factors in CLL. Leukemia Supplements, 1, S29–S30.
41. Filip, A. A., Grenda, A., Popek, S., Koczkodaj, D., Michalak-Wojnowska, M., Budzyٌöski, M., … Giannopoulos, K. (2016). Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL—Another piece in the puzzle. Annals of Hematology, 96(1), 33–50.
42. Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N., Tavolaro, S., … Messina, M. (2007). Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 109(11), 4944–4951.
43. Gandhi, V. (2010). Targeting kinases in CML CLL. Blood, 116(12), 1999–2000.
44. Gholamin, S., Pasdar, A., Sadegh Khorrami, M., Mirzaei, H., Reza Mirzaei, H., Salehi, R., … Avan, A. (2016). The potential for circulating microRNAs in the diagnosis of myocardial infarction: A novel approach to disease diagnosis and treatment. Current Pharmaceutical Design, 22(3), 397–403.
45. Ghosh, A. K., Shanafelt, T. D., Cimmino, A., Taccioli, C., Volinia, S., Liu, C.-G., … Giaccia, A. J. (2009). Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood, 113(22), 5568–5574.
46. Giacopelli, B., Ruppert, A. S., Wu, Y.-Z., Rassenti, L. Z., Wierda, W. G., Rai, K. R., … Byrd, J. C. (2016). Comparative evaluation of prognostic factors that assess the natural history of chronic lymphocytic leukemia. Blood, 128(22), 968–968.
47. Gounaris-Shannon, S., & Chevassut, T. (2013). The role of miRNA in haematological malignancy. Bone Marrow Research, 2013, 12. http://doi.org/10.1155/2013/269107
48. Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dِöhner, H., … Rai, K. R. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111(12), 5446–5456.
49. Hegde, G. V., Peterson, K. J., Emanuel, K., Mittal, A. K., Joshi, A. D., Dickinson, J. D., … Vose, J. M. (2008). Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target. Molecular Cancer Research, 6(12), 1928–1936.
50. Herishanu, Y., Katz, B.-Z., Lipsky, A., & Wiestner, A. (2013). Biology of chronic lymphocytic leukemia in different microenvironments: Clinical and therapeutic implications. Hematology/Oncology Clinics of North America, 27(2), 173–206.
51. Houlston, R., Catovsky, D., & Yuille, M. (2002). Genetic susceptibility to chronic lymphocytic leukemia. Leukemia, 16(6), 1008–1014.
52. Jansson, M. D., & Lund, A. H. (2012). MicroRNA and cancer. Molecular Oncology, 6(6), 590–610.
53. Kelloff, G. J., & Sigman, C. C. (2012). Cancer biomarkers: Selecting the right drug for the right patient. Nature Reviews Drug Discovery, 11(3), 201–214.
54. Kiefer, Y., Schulte, C., Tiemann, M., & Bullerdiek, J. (2012). Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation. The Application of Clinical Genetics, 5, 21.
55. Konoplev, S. N., Fritsche, H. A., O'Brien, S., Wierda, W. G., Keating, M. J., Gornet, T. G., … Johnson, M. R. (2010). High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. American Journal of Clinical pathology, 134(3), 472–477.
56. Koulikov, V., Barnes, S., & Even-Sapir, E. (2016). 68 Ga-PSMA PET-CT in patients with newly diagnosed high-risk prostate cancer. Journal of Nuclear Medicine, 57(supplement 2), 1540–1540.
57. Letai, A. G. (2008). Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Reviews Cancer, 8(2), 121–132.
58. Li, S., Moffett, H. F., Lu, J., Werner, L., Zhang, H., Ritz, J., … Novina, C. D. (2011). MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS ONE, 6(3), e16956.
59. Lodé, L., Cymbalista, F., & Soussi, T. (2016). Genetic profiling of CLL: A ‘TP53 addict'perspective. Cell Death & Disease, 7(1), e2042.
60. Magnac, C., Porcher, R., Davi, F., Nataf, J., Payelle-Brogard, B., Tang, R., … Ajchenbaum-Cymbalista, F. (2003). Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia, 17(1), 133–137.
61. Malcikova, J., Smardova, J., Rocnova, L., Tichy, B., Kuglik, P., Vranova, V., … Brychtova, Y. (2009). Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: Selection, impact on survival, and response to DNA damage. Blood, 114(26), 5307–5314.
62. Marton, S., Garcia, M., Robello, C., Persson, H., Trajtenberg, F., Pritsch, O., … Cayota, A. (2008). Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia, 22(2), 330–338.
63. Mauro, F., Chauvie, S., Paoloni, F., Biggi, A., Cimino, G., Rago, A., … Bellٍö, M. (2015). Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia, 29(6), 1360–1365.
64. Mertens, D., & Stilgenbauer, S. (2014). Prognostic and predictive factors in patients with chronic lymphocytic leukemia: Relevant in the era of novel treatment approaches? Journal of Clinical Oncology, 32(9), 869–872.
65. Migliazza, A., Bosch, F., Komatsu, H., Cayanis, E., Martinotti, S., Toniato, E., … Murty, V. (2001). Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood, 97(7), 2098–2104.
66. Mirzaei, H., Sahebkar, A., Jaafari, M. R., Goodarzi, M., & Mirzaei, H. R. (2016a). Diagnostic and therapeutic potential of exosomes in cancer: The beginning of a new tale? Journal of Cellular Physiology http://doi.org/10.1002/jcp.25739 [Epub ahead of print].
67. Mirzaei, H., Sahebkar, A., Mohammadi, M., Yari, R., Salehi, H., Jafari, M. H., … Mirzaei, H. (2016b). Circulating microRNAs in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers. Current Pharmaceutical Design 22(34), 5257–5269.
68. Mirzaei, H., Momeni, F., Saadatpour, L., Sahebkar, A., Goodarzi, M., Masoudifar, A., … Jaafari, M. R. (2017). MicroRNA: Relevance to stroke diagnosis, prognosis and therapy. Journal of Cellular Physiology, 9(10), 25787. [Epub ahead of print]
69. Mirzaei, H., Gholamin, S., Shahidsales, S., Sahebkar, A., Jafaari, M. R., Mirzaei, H. R., … Avan, A. (2016). MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. European Journal of Cancer, 53, 25–32.
70. Mirzaei, H., Khataminfar, S., Mohammadparast, S., Shahid Sales, S., Maftouh, M., Mohammadi, M., … Avan, A. (2016). Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in gastric cancer: Current status and future perspectives. Current Medicinal Chemistry, 23(36), 4135–4150.
71. Mirzaei, H., Naseri, G., Rezaee, R., Mohammadi, M., Banikazemi, Z., Reza Mirzaei, H., … Sahebkar, A. (2016). Curcumin: A new candidate for melanoma therapy? International Journal of Cancer, 139(8), 1683–1695.
72. Mohammadi, M., Goodarzi, M., Jaafari, M. R., Mirzaei, H. R., & Mirzaei, H. (2016). Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Therapy, 23(11), 371–372.
73. Monticelli, S., Ansel, K. M., Xiao, C., Socci, N. D., Krichevsky, A. M., Thai, T.-H., … Rajewsky, K. (2005). MicroRNA profiling of the murine hematopoietic system. Genome Biology, 6(8), 1.
74. Moore, V. D. G., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007). Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. The Journal of Clinical Investigation, 117(1), 112–121.
75. Moussay, E., Wang, K., Cho, J.-H., van Moer, K., Pierson, S., Paggetti, J., … Berchem, G. (2011). MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 108(16), 6573–6578.
76. Mraz, M., & Kipps, T. J. (2013). MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leukemia & Lymphoma, 54(8), 1836–1839.
77. Mraz, M., Pospisilova, S., Malinova, K., Slapak, I., & Mayer, J. (2009). MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leukemia & Lymphoma, 50(3), 506–509.
78. Muroi, K., Nakamurat, M., Amemiya, Y., Suda, T., & Miura, Y. (1995). Expression of c-kit receptor (CD 117) and CD34 in leukemic cells. Leukemia & Lymphoma, 16(3-4), 297–305.
79. Musto, P., Negrini, M., De Luca, L., & Cuneo, A. (2016). Dissecting chronic lymphocytic leukemia with 13q-using microRNA expression profile: “Editorial for the paper “MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion”. Leukemia Research, 47, 114–115.
80. O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., & Baltimore, D. (2010). Physiological and pathological roles for microRNAs in the immune system. Nature Reviews Immunology, 10(2), 111–122.
81. Oppezzo, P., & Dighiero, G. (2013). Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’. Blood Cancer Journal, 3(9), e149.
82. Ortiz-Maldonado, V., García-Morillo, M., & Delgado, J. (2014). The biology behind PI3 K inhibition in chronic lymphocytic leukaemia. Therapeutic Advances in Hematology, 2040620714561581.
83. Ouillette, P., Collins, R., Shakhan, S., Li, J., Peres, E., Kujawski, L., … Shedden, K. (2011). Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood, 118(11), 3051–3061.
84. Paggetti, J., Haderk, F., Seiffert, M., Janji, B., Distler, U., Ammerlaan, W., … Solary, E. (2015). Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood, 126(9), 1106–1117.
85. Palamarchuk, A., Yan, P. S., Zanesi, N., Wang, L., Rodrigues, B., Murphy, M., … Alder, H. (2012). Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences, 109(7), 2555–2560.
86. Pallasch, C. P., Patz, M., Park, Y. J., Hagist, S., Eggle, D., Claus, R., … Claasen, J. (2009). MiRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood, 114(15), 3255–3264.
87. Pekarsky, Y., Santanam, U., Cimmino, A., Palamarchuk, A., Efanov, A., Maximov, V., … Rassenti, L. (2006). Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Research, 66(24), 11590–11593.
88. Pizzimenti, S., Ferracin, M., Sabbioni, S., Toaldo, C., Pettazzoni, P., Dianzani, M. U., … Barrera, G. (2009). MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radical Biology and Medicine, 46(2), 282–288.
89. Ramkissoon, S. H., Mainwaring, L. A., Ogasawara, Y., Keyvanfar, K., McCoy, J. P., Sloand, E. M., … Young, N. S. (2006). Hematopoietic-specific microRNA expression in human cells. Leukemia Research, 30(5), 643–647.
90. Rashidi, B., Hoseini, Z., Sahebkar, A., & Mirzaei, H. (2016). Anti-atherosclerotic effects of vitamins d and e in suppression of atherogenesis. Journal of Cellular Physiology, [Epub ahead of print].
91. Rassenti, L. Z., Jain, S., Keating, M. J., Wierda, W. G., Grever, M. R., Byrd, J. C., … Neuberg, D. S. (2008). Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood, 112(5), 1923–1930.
92. Rizzotto, L., Bottoni, A., Lai, T.-H., Liu, C., Yan, P. S., Ozer, H. G., … Blachly, J. S. (2016). Role of histone deacetylase-Mediated gene silencing in chronic lymphocytic leukemia progression. Blood, 128(22), 2705–2705.
93. Rodríguez, A. E., Hernández, J., Benito, R., Gutiérrez, N. C., Garcáa, J. L., Hernández-Sánchez, M., … Fisac, R. (2012). Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. PLoS ONE, 7(11), e48485.
94. Rogalinska, M., Kilianska, Z. (2012). Targeting bcl-2 in CLL. Current Medicinal chemistry, 19(30), 5109–5115.
95. Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., … Powell, J. (2001). Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. The Journal of Experimental Medicine, 194(11), 1639–1648.
96. Rossi, S., Shimizu, M., Barbarotto, E., Nicoloso, M. S., Dimitri, F., Sampath, D., … Rassenti, L. Z. (2010). MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 116(6), 945–952.
97. Rossi, D., Rasi, S., Fabbri, G., Spina, V., Fangazio, M., Forconi, F., … Cerri, M. (2012). Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood, 119(2), 521–529.
98. Rozovski, U., Hazan-Halevy, I., Calin, G., Harris, D., Li, P., Liu, Z., … Estrov, Z. (2016). Describing a transcription factor dependent regulation of the MicroRNA transcriptome. JoVE (Journal of Visualized Experiments), (112), e53300–e53300.
99. Saadatpour, Z., Bjorklund, G., Chirumbolo, S., Alimohammadi, M., Ehsani, H., Ebrahiminejad, H., … Sahebkar, A. (2016). Molecular imaging and cancer gene therapy. Cancer Gene Therapy.
100. Saadatpour, L., Fadaee, E., Fadaei, S., Mansour, R. N., Mohammadi, M., Mousavi, S., … Mirzaei, H. (2016). Glioblastoma: Exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Therapy, 23(12), 415–418.
101. Saadatpour, Z., Rezaei, A., Ebrahimnejad, H., Baghaei, B., Bjorklund, G., Chartrand, M., … Mirzaei, H. (2016). Imaging techniques: New avenues in cancer gene and cell therapy. Cancer Gene Therapy, 24(1), 1–5.
102. Salarini, R., Sahebkar, A., Mirzaei, H., Jaafari, M., Riahi, M., Hadjati, J., … Mirzaei, H. (2015). Epi-drugs and Epi-miRs: Moving beyond current cancer therapies. Current Cancer Drug Targets, 16(9), 773–788.
103. Saleh, L., Wang, W., Herman, S., Saba, N., Anastas, V., Barber, E., … Sarasua, S. (2016). Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia, 31(2), 340–349.
104. Sandhu, S. K., Fassan, M., Volinia, S., Lovat, F., Balatti, V., Pekarsky, Y., & Croce, C. M. (2013). B-cell malignancies in microRNA Eµ-miR-17∼ 92 transgenic mice. Proceedings of the National Academy of Sciences, 110(45), 18208–18213.
105. Sayed, D., & Abdellatif, M. (2011). MicroRNAs in development and disease. Physiological Reviews, 91(3), 827–887.
106. Schroers, R., Griesinger, F., Trümper, L., Haase, D., Kulle, B., Klein-Hitpass, L., … Dürig, J. (2005). Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia, 19(5), 750–758.
107. Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015). Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. Cancers, 7(4), 2443–2458.
108. Simonian, M., Mosallayi, M., & Mirzaei, H. (2016). Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. Journal of cancer research and therapeutics.
109. Smallwood, D. T., Apollonio, B., Willimott, S., Lezina, L., Alharthi, A., Ambrose, A. R., … Wagner, S. D. (2016). Extracellular vesicles released by CD40/IL-4–stimulated CLL cells confer altered functional properties to CD4+ T cells. Blood, 128(4), 542–552.
110. Smolewski, P., Witkowska, M., & Korycka-Wo owiec, A. (2013). New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia. ISRN Oncology, 2013, 7. http://doi.org/10.1155/2013/740615
111. Srivastava, S., Tsongalis, G. J., & Kaur, P. (2016). Role of microRNAs in regulation of the TNF/TNFR gene superfamily in chronic lymphocytic leukemia. Clinical Biochemistry, 49(16), 1307–1310.
112. Starnes, L., Sorrentino, A., Ferracin, M., Negrini, M., Pelosi, E., Nervi, C., & Peschle, C. (2010). A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34+ progenitors and CML cells. Leukemia, 24(6), 1220–1223.
113. Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., … DeClerck, Y. A. (2012). Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Research, 72(10), 2473–2480.
114. Tavolaro, S., Colombo, T., Chiaretti, S., Peragine, N., Fulci, V., Ricciardi, M. R., … Marinelli, M. (2015). Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. Genes, Chromosomes and Cancer, 54(4), 222–234.
115. Teimori, H., Ashoori, S., Akbari, M. T., Naeini, M. M., & Chaleshtori, M. H. (2013). FISH analysis for del6q21 and del17p13 in B-cell chronic lymphocytic leukemia in iranians. Iranian Red Crescent Medical Journal, 15(2), 107.
116. Tian, T., Wang, M., & Ma, D. (2014). TNF-α, a good or bad factor in hematological diseases? Stem Cell Investigation, 1(1), 12. http://doi.org/10.3978/j.issn.2306-9759.2014.04.02
117. Tie, Y., Liu, B., Fu, H., & Zheng, X. (2009). Circulating miRNA and cancer diagnosis. Science in China Series C: Life Sciences, 52(12), 1117–1122.
118. Tobin, G., Thunberg, U., Johnson, A., Thِörn, I., Sِöderberg, O., Hultdin, M., … Sundstrِöm, C. (2002). Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood, 99(6), 2262–2264.
119. Undi, R. B., Kandi, R., & Gutti, R. K. (2013). MicroRNAs as haematopoiesis regulators. Advances in Hematology, 2013, 695754. http://doi.org/10.1155/2013/695754
120. Visone, R., Rassenti, L. Z., Veronese, A., Taccioli, C., Costinean, S., Aguda, B. D., … Balatti, V. (2009). Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 114(18), 3872–3879.
121. Visone, R., Veronese, A., Rassenti, L. Z., Balatti, V., Pearl, D. K., Acunzo, M., … Croce, C. M. (2011). MiR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood, 118(11), 3072–3079.
122. Wang, Y., & Lee, C. G. (2009). MicroRNA and cancer–focus on apoptosis. Journal of Cellular and Molecular Medicine, 13(1), 12–23.
123. Wang, L. Q., Kwong, Y. L., Kho, C. S. B., Wong, K. F., Wong, K. Y., Ferracin, M., … Chim, C. S. (2013). Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFκB pathway. Molecular Cancer, 12(1), 1.
124. Wiestner, A., Rosenwald, A., Barry, T. S., Wright, G., Davis, R. E., Henrickson, S. E., … Davis, Z. (2003). ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood, 101(12), 4944–4951.
125. Willems, E., Humblet-Baron, S., Dengis, O., Seidel, L., Beguin, Y., & Baron, F. (2010). Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplantation, 45(9), 1442–1448.
126. Willimott, S., & Wagner, S. (2012). Stromal cells and CD40 ligand (CD154) alter the miRNome and induce miRNA clusters including, miR-125b/miR-99a/let-7c and miR-17-92 in chronic lymphocytic leukaemia. Leukemia, 26(5), 1113–1116.
127. Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012). The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood, 120(6), 1175–1184.
128. Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., … Rajewsky, K. (2008). Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 9(4), 405–414.
129. Yeh, Y.-Y., Ozer, H. G., Lehman, A. M., Maddocks, K., Yu, L., Johnson, A. J., & Byrd, J. C. (2015). Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood, 125(21), 3297–3305.
130. Zanette, D., Rivadavia, F., Molfetta, G., Barbuzano, F., Proto-Siqueira, R., Falco, R., … Silva-Jr, W. (2007). MiRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Brazilian Journal of Medical and Biological Research, 40(11), 1435–1440.
131. Zenz, T., Mertens, D., Küppers, R., Dِöhner, H., & Stilgenbauer S. (2010). From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Reviews Cancer, 10(1), 37–50.
132. Zhang, W. G, Chen, L., Dong, Q., He, J., Zhao, H.-D., Li, F., & Li, H. (2013). Mmu-miR-702 functions as an anti-apoptotic mirtron by mediating ATF6 inhibition in mice. Gene, 531(2), 235–242.
133. Zhou, B., Wang, S., Mayr, C., Bartel, D. P., & Lodish, H. F. (2007). MiR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proceedings of the National Academy of Sciences, 104(17), 7080–7085.
134. Zhu, D.-X., Zhu, W., Fang, C., Fan, L., Zou, Z.-J., Wang, Y.-H., … Liu, P. (2012). MiR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis, 33(7), 1294–1301.